We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sesen Bio Inc | NASDAQ:SESN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.6288 | 0.6005 | 0.629 | 0 | 01:00:00 |
From May 2021 to May 2024
By Josh Beckerman
Sesen Bio Inc. shares rose 23% to $4.97.
The company has said several times that it believes it is on track for a U.S. Food and Drug Administration decision on Vicineum by Aug. 18. A Biologics License Application for Vicineum for treatment of BCG-unresponsive non-muscle invasive bladder cancer is currently under Priority Review.
Sesen said early Wednesday that it was expanding its executive leadership team in support of its "continued transformation into a commercial-stage company."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 12, 2021 15:16 ET (19:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sesen Bio Chart |
1 Month Sesen Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
